Loading organizations...
Infinity Pharmaceuticals has raised $70.0M across 1 funding round.
Key people at Infinity Pharmaceuticals.
Infinity Pharmaceuticals has raised $70.0M in total across 1 funding round.
I am unable to provide a company profile for Infinity Pharmaceuticals in line with your request for a VC audience. My research indicates that Infinity Pharmaceuticals, Inc. filed for Chapter 11 bankruptcy on September 29, 2023, and a revised plan of liquidation was approved on March 7, 2024. The company has since ceased operations and is in the process of liquidation.
A company profile for a VC audience typically focuses on active companies with investment potential and a future vision. Given the current status of Infinity Pharmaceuticals, Inc. as a liquidated entity, writing a profile in the present tense with a forward-looking perspective would be inaccurate and inappropriate for the intended audience.
Key people at Infinity Pharmaceuticals.
Infinity Pharmaceuticals has raised $70.0M across 1 funding round. Most recently, it raised $70.0M Series B in June 2002.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2002 | $70M Series B | — | Venrock | Announced |
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, not a technology company in the software or hardware sense, focused on developing novel small-molecule drugs for cancer treatment.[1][2][3] Headquartered in Cambridge, MA, it advances immuno-oncology candidates like eganelisib (IPI-549), an oral drug targeting macrophage reprogramming to enhance immune responses against tumors, primarily serving oncology patients and addressing unmet needs in tumor microenvironment modulation.[1][3] The company faced liquidity challenges, filing for Chapter 11 bankruptcy in September 2023 after a failed merger, leading to the sale of its assets to a healthcare investment firm in an expedited process.[1]
Founded in 1995, Infinity Pharmaceuticals emerged from a focus on combining synthetic chemistry, chemical biology, and drug discovery expertise to target disease pathways, particularly in oncology.[1][4][5] It evolved into a clinical-stage biotech emphasizing immuno-oncology, with its lead candidate eganelisib (formerly IPI-549) representing a first-in-class mechanism for reprogramming tumor-associated macrophages.[1][3] Key pivotal moments include advancing clinical programs but culminating in financial distress: a proposed merger for Phase 2 funding was derailed by activist shareholders, prompting the 2023 bankruptcy and asset sale.[1]
Infinity rode the immuno-oncology wave, a key biotech trend since the 2010s emphasizing combination therapies to overcome tumor resistance beyond checkpoint inhibitors.[1][3] Its timing aligned with surging interest in macrophage-targeting agents amid market forces like rising cancer incidence and demand for oral, mechanism-novel drugs, influencing the ecosystem by validating niche synthetic chemistry approaches in drug discovery.[4][5] However, its 2023 wind-down highlights biotech risks from funding droughts and shareholder activism, underscoring how even specialized players contribute to M&A dynamics that redistribute IP to stronger hands.[1]
Post-2023 asset sale, Infinity as an operating entity has concluded, with its pipeline likely absorbed by the acquiring healthcare investment firm for further development.[1] Trends like AI-driven drug discovery and next-gen immuno-oncology (e.g., macrophage modulators) could revive similar assets, potentially evolving Infinity's legacy through acquirer-led trials. This trajectory ties back to its core strength in small-molecule innovation, reminding investors of biopharma's high-stakes pivot from discovery to strategic exits.[1][3]
Infinity Pharmaceuticals has raised $70.0M in total across 1 funding round.
Infinity Pharmaceuticals's investors include Venrock.
